Furthermore, CD24 may play a role in chemotherapy resistance in triple‐negative breast cancer (TNBC) (Deng et al., 2017), HCC (Lu et al., 2018), and endometrial cancer (Ono et al., 2015), further implicating it as a potential drug target (Ono et al., 2015; Runz et al., 2008; Schabath et al., 2006). This evidence concerns the gene CD24 and endometrial cancer.